AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 375342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 375342 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY g 5421 (Acarbose)
Number of subjects: 0
Study 31856945 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-session smoking cessation treatment
Number of subjects: 529
Study 31508729 — intervention group
Group type: EXPERIMENTAL
Intervention: HyFlex CM (Coltene‐Whaledent, Altstetten, Switzerland)
Number of subjects: 24
Study 31508729 — intervention group
Group type: COMPARATOR
Intervention: ProTaper Next (Dentsply Sirona, Ballaigues, Switzerland)
Number of subjects: 24
Study 27779500 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐go device training
Number of subjects: 19
Study 27779500 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy programs
Number of subjects: 19
Study 25607226 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous caffeine citrate (20 mg/kg) before 2 hours of age
Number of subjects: 21
Study 25607226 — intervention group
Group type: COMPARATOR
Intervention: Placebo at 12 hours of age
Number of subjects: 21
Study 23433492 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation plus usual care (SCS group)
Number of subjects: 45
Study 23433492 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone (UC group)
Number of subjects: 45
Study 23433492 — intervention group
Group type: COMPARATOR
Intervention: Both groups (SCS and UC)
Number of subjects: 45
Study 22002968 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% HES 130/0.4
Number of subjects: 70
Study 22002968 — intervention group
Group type: COMPARATOR
Intervention: 4% gelatin
Number of subjects: 70
Study 19527897 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE)
Number of subjects: 72
Study 19527897 — intervention group
Group type: COMPARATOR
Intervention: Systemic methotrexate (MTX)
Number of subjects: 72
Study 17325606 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-minute HIV and alcohol risk reduction behavioral skills intervention
Number of subjects: 143
Study 17325606 — intervention group
Group type: COMPARATOR
Intervention: 20-minute HIV education condition (Control)
Number of subjects: 143
Study 14702024 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent evaluators' guesses about treatment condition during post-treatment assessments
Number of subjects: 170
Study 11455377 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified composite
Number of subjects: 98
Study 11455377 — intervention group
Group type: COMPARATOR
Intervention: Conventional glass ionomer
Number of subjects: 98
Study 9741864 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization with paternal leukocytes
Number of subjects: 0
Study 9741864 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 0
Study 8050210 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) erythropoietin (EPO) at a dose of 120 iu/kg/week
Number of subjects: 16
Study 8050210 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) erythropoietin (EPO) at a dose of 120 iu/kg/week
Number of subjects: 16
Study 8050210 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) EPO
Number of subjects: 16
Study 8050210 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) EPO
Number of subjects: 16
Study 8050210 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO withdrawal
Number of subjects: 16
Study 8050210 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) EPO and Intravenous (IV) EPO
Number of subjects: 16
Study 3391624 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytetracycline and pyridostigmine in combination
Number of subjects: 12
Study 3391624 — intervention group
Group type: COMPARATOR
Intervention: Oxytetracycline alone
Number of subjects: 12
Study 3391624 — intervention group
Group type: COMPARATOR
Intervention: Pyridostigmine alone
Number of subjects: 12
Study 31009861 — intervention group
Group type: EXPERIMENTAL
Intervention: Teach Two (simple structured direction)
Number of subjects: 42
Study 31009861 — intervention group
Group type: COMPARATOR
Intervention: Social (unstructured direction)
Number of subjects: 42
Study 31009861 — intervention group
Group type: COMPARATOR
Intervention: Teach Many (complex structured direction)
Number of subjects: 42
Study 28215611 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolotherapy injection (n=60)
Number of subjects: 120
Study 28215611 — intervention group
Group type: COMPARATOR
Intervention: Exercise (control group; n=60)
Number of subjects: 120
Study 25579292 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 µg phenylephrine
Number of subjects: 120
Study 25579292 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 µg phenylephrine
Number of subjects: 120
Study 25579292 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 µg phenylephrine
Number of subjects: 120
Study 25579292 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional doses of phenylephrine
Number of subjects: 120
Study 25579292 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of additional boluses
Number of subjects: 120
Study 25579292 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of hypotensive episodes
Number of subjects: 120
Study 25579292 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive hypertension or bradycardia
Number of subjects: 120
Study 22571806 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Response Questionnaire
Number of subjects: 640
Study 22571806 — intervention group
Group type: EXPERIMENTAL
Intervention: Chalder Fatigue Scale
Number of subjects: 640
Study 22571806 — intervention group
Group type: EXPERIMENTAL
Intervention: Work and Social Adjustment Scale
Number of subjects: 640
Study 21719110 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1g BID
Number of subjects: 149
Study 21719110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 18306478 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 122
Study 18306478 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 122
Study 16957412 — intervention group
Group type: EXPERIMENTAL
Intervention: 458 kcal diet for 1 month (Group A)
Number of subjects: 67
Study 16957412 — intervention group
Group type: COMPARATOR
Intervention: 800 kcal diet for 3 months (Group B)
Number of subjects: 67
Study 12851016 — intervention group
Group type: EXPERIMENTAL
Intervention: SF‐36 Health Survey
Number of subjects: 252
Study 12851016 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 252
Study 11099086 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin suspension (10 mg/kg twice a day + im placebo; n = 95)
Number of subjects: 201
Study 11099086 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular ceftriaxone (50 mg/kg/day + placebo suspension; n = 106)
Number of subjects: 201
Study 11099086 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin suspension
Number of subjects: 201
Study 11099086 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular ceftriaxone
Number of subjects: 201
Study 11099086 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 201
Study 11099086 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 201
Study 9124977 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 50 mg and Amiloride 5 mg orally added to furosemide treatment
Number of subjects: 210
Study 9124977 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (large doses > or = 80 mg/24 h)
Number of subjects: 210
Study 8197425 — intervention group
Group type: EXPERIMENTAL
Intervention: Less than lobar resections
Number of subjects: 170
Study 3537596 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanostomy tubes
Number of subjects: 65
Study 3537596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 3537596 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfisoxazole
Number of subjects: 65
Study 30144986 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antibiotic solution (1 mg/mL)
Number of subjects: 47
Study 30144986 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide/chlorhexidine paste
Number of subjects: 47
Study 26400827 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 11145
Study 26400827 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 11145
Study 25496415 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dietary α-linolenic acid (ALA)
Number of subjects: 0
Study 25496415 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 22766420 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish version of the SAQLI questionnaire
Number of subjects: 162
Study 22766420 — intervention group
Group type: COMPARATOR
Intervention: SF-36, FOSQ, Epworth scale
Number of subjects: 162
Study 20167306 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive training (MCT)
Number of subjects: 30
Study 20167306 — intervention group
Group type: COMPARATOR
Intervention: Active control intervention
Number of subjects: 30
Study 18090506 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 85
Study 16864836 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (VPA)
Number of subjects: 68
Study 16864836 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin (PHT)
Number of subjects: 68
Study 12568061 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeling time
Number of subjects: 1188
Study 12568061 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression adjustment for covariates
Number of subjects: 1188
Study 10828571 — intervention group
Group type: EXPERIMENTAL
Intervention: Three successive measurements with a 5‐min interval in prone position
Number of subjects: 138
Study 10828571 — intervention group
Group type: EXPERIMENTAL
Intervention: Three successive measurements with a 5‐min interval in supine position
Number of subjects: 138
Study 10828571 — intervention group
Group type: EXPERIMENTAL
Intervention: Single measurement before feeding regardless of body position
Number of subjects: 138
Study 9097211 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate caregiver training group
Number of subjects: 96
Study 9097211 — intervention group
Group type: COMPARATOR
Intervention: Wait-list caregiver training group
Number of subjects: 96
Study 9097211 — intervention group
Group type: COMPARATOR
Intervention: Memory retraining group
Number of subjects: 96
Study 9097211 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver training (all groups)
Number of subjects: 96
Study 1351405 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous medication with neuroleptic drugs
Number of subjects: 364
Study 1351405 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent medication with crisis intervention
Number of subjects: 364
Study 1351405 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent medication with early intervention
Number of subjects: 364
Study 1351405 — intervention group
Group type: COMPARATOR
Intervention: Neuroleptic drugs
Number of subjects: 364
Study 1351405 — intervention group
Group type: COMPARATOR
Intervention: Low potency neuroleptics
Number of subjects: 364
Study 1351405 — intervention group
Group type: COMPARATOR
Intervention: Oral neuroleptics
Number of subjects: 364
Study 2858619 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (azathioprine and prednisolone)
Number of subjects: 50
Study 2858619 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine withdrawal
Number of subjects: 50
Study 31869257 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol 85%
Number of subjects: 30
Study 31869257 — intervention group
Group type: COMPARATOR
Intervention: NB-UVB
Number of subjects: 30
Study 31298607 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Chloramphenicol 0.5%-Betamethasone 0.2% (CB)
Number of subjects: 31
Study 31298607 — intervention group
Group type: COMPARATOR
Intervention: Topical Chloramphenicol 0.5%-Betamethasone 0.2% (CB) associated with Sodium Hyaluronate/Trehalose/Carbomer Gel (HTC-gel)
Number of subjects: 31
Study 30421481 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab on top of atorvastatin 40 mg
Number of subjects: 308
Study 30421481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study 26787116 — intervention group
Group type: EXPERIMENTAL
Intervention: SPS (sport students)
Number of subjects: 114
Study 26787116 — intervention group
Group type: EXPERIMENTAL
Intervention: DES (dental students)
Number of subjects: 114
Study 24113076 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized CBM‐I
Number of subjects: 54
Study 24113076 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-generation CBM‐I
Number of subjects: 54
Study 24113076 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study 22449170 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage treatment applied by a physical therapist on the posterior deltoid, infraspinatus, and teres minor for 18 minutes, two times a week for 4 weeks.
Number of subjects: 60
Study 22449170 — intervention group
Group type: COMPARATOR
Intervention: Control group received light hand touch on the muscles for 10 minutes, two times a week for 4 weeks.
Number of subjects: 60
Study 22449170 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage treatment
Number of subjects: 60
Study 20851321 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory training
Number of subjects: 0
Study 20851321 — intervention group
Group type: COMPARATOR
Intervention: Health promotion training (control)
Number of subjects: 0
Study 17913231 — intervention group
Group type: EXPERIMENTAL
Intervention: Botanical extracts from Epimedium sp.
Number of subjects: 0
Study 17913231 — intervention group
Group type: COMPARATOR
Intervention: Oestrogenic drugs
Number of subjects: 0
Study 15156426 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly administered antiretroviral therapy (DAART)
Number of subjects: 72
Study 15156426 — intervention group
Group type: COMPARATOR
Intervention: Self-administered therapy
Number of subjects: 72
Study 11422149 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS; 200 microg/day)
Number of subjects: 440
Study 11422149 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide reservoir powder device (BUD RPD; 200 microg/day)
Number of subjects: 440
Study 9495605 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline treatment (11 weeks) in fibromyalgia patients
Number of subjects: 41
Study 9495605 — intervention group
Group type: COMPARATOR
Intervention: Patients with major depression
Number of subjects: 41
Study 9495605 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibromyalgia patients
Number of subjects: 41
Study 9495605 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibromyalgia patients and major depression patients
Number of subjects: 41
Study 9495605 — intervention group
Group type: COMPARATOR
Intervention: Normal volunteers
Number of subjects: 41
Study 8285383 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise lowering of hemoglobin concentration through venesections (average decrease from 151 +/- 4 to 121 +/- 3 g/L)
Number of subjects: 12
Study 8285383 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise lowering of hemoglobin concentration through venesections
Number of subjects: 12
Study 8285383 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise lowering of hemoglobin concentration through venesections (average volume of about 1.4 liters whole blood within fourteen days)
Number of subjects: 12
Study 8285383 — intervention group
Group type: COMPARATOR
Intervention: Control group (not subjected to venesections)
Number of subjects: 12
Study 3190968 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine infusion at 20 mg h‐1
Number of subjects: 20
Study 3190968 — intervention group
Group type: COMPARATOR
Intervention: 0.08% bupivacaine infusion at 20 mg h‐1
Number of subjects: 20
Study 30193564 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention
Number of subjects: 116
Study 30193564 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 116
Study 31227852 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar resurfacing
Number of subjects: 60
Study 31227852 — intervention group
Group type: COMPARATOR
Intervention: Non-resurfacing
Number of subjects: 60
Study 31227852 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 28689647 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates method physical activity programme (2 weekly sessions for 8 weeks)
Number of subjects: 105
Study 28689647 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Pilates programme)
Number of subjects: 105
Study 25261268 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based telemonitored Nordic walking (NW) training (n=77), five times weekly for eight weeks
Number of subjects: 111
Study 25261268 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone (control group, n=34)
Number of subjects: 111
Study 24215511 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus docetaxel
Number of subjects: 251
Study 24215511 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel alone
Number of subjects: 251
Study 24215511 — intervention group
Group type: EXPERIMENTAL
Intervention: RRM1 aberrations
Number of subjects: 251
Study 24215511 — intervention group
Group type: EXPERIMENTAL
Intervention: RRM2B aberrations
Number of subjects: 251
Study 24215511 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene status
Number of subjects: 251
Study 21692860 — intervention group
Group type: EXPERIMENTAL
Intervention: GEKG
Number of subjects: 10
Study 21692860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 18165600 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 400 mg preoperatively, administered every 6 hours up to a total of 1200 mg
Number of subjects: 70
Study 18165600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 18165600 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 70
Study 16728515 — intervention group
Group type: EXPERIMENTAL
Intervention: Apnea divers
Number of subjects: 16
Study 16728515 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 15253736 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin and heparin (5 mg/mL)
Number of subjects: 50
Study 15253736 — intervention group
Group type: COMPARATOR
Intervention: Standard heparin (5000 IU/mL) alone
Number of subjects: 50
Study 11739835 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabinoid receptor agonist nabilone
Number of subjects: 7
Study 11739835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 9415539 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified total lymphoid irradiation plus low dose prednisone (TLI-LDP)
Number of subjects: 46
Study 9415539 — intervention group
Group type: COMPARATOR
Intervention: Sham TLI plus identical prednisone therapy (sham TLI-LDP)
Number of subjects: 46
Study 8512762 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 31
Study 8512762 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 31
Study 3687353 — intervention group
Group type: COMPARATOR
Intervention: Neutral recording with no verbal content (Groups I and II)
Number of subjects: 32
Study 3687353 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental recording with a positive suggestion for a rapid recovery (Group III)
Number of subjects: 32
Study 3687353 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-prepared message (Group IV)
Number of subjects: 32
Study 31662387 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic treatment (Enterococcus faecalis)
Number of subjects: 120
Study 31662387 — intervention group
Group type: COMPARATOR
Intervention: Open-label placebo
Number of subjects: 120
Study 31662387 — intervention group
Group type: COMPARATOR
Intervention: Concealed placebo treatment
Number of subjects: 120
Study 31662387 — intervention group
Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 120
Study 27243570 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT), 24 International Units
Number of subjects: 32
Study 27243570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 25981191 — intervention group
Group type: EXPERIMENTAL
Intervention: SB010 (10 mg, inhalation once daily for 28 days)
Number of subjects: 40
Study 25981191 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inhalation once daily for 28 days)
Number of subjects: 40
Study 24038301 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined pharmacotherapy and psychotherapy
Number of subjects: 821
Study 24038301 — intervention group
Group type: EXPERIMENTAL
Intervention: MADRS total score and subscales
Number of subjects: 821
Study 24038301 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-factor model (Sadness, Negative Thoughts, Detachment, Neurovegetative symptoms)
Number of subjects: 821
Study 24038301 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical model of four factors
Number of subjects: 821
Study 21385504 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiced rice meal
Number of subjects: 54
Study 21385504 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple pie yogurt
Number of subjects: 54
Study 21385504 — intervention group
Group type: EXPERIMENTAL
Intervention: Retro-nasal aroma release measurement
Number of subjects: 54
Study 19620438 — intervention group
Group type: EXPERIMENTAL
Intervention: CT screening
Number of subjects: 53457
Study 19620438 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality assurance procedures
Number of subjects: 53457
Study 16874872 — intervention group
Group type: EXPERIMENTAL
Intervention: S. boulardii (250 mg bid)
Number of subjects: 100
Study 16874872 — intervention group
Group type: COMPARATOR
Intervention: Control (ORS and nutritional support only)
Number of subjects: 100
Study 12972483 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised training on rubber mannequins
Number of subjects: 40
Study 12972483 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional training on patients in hospital joint injection clinics
Number of subjects: 40